Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain investors valued at aggregate gross proceeds of approximately $16.0 million (effective 2024-03-11).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain investors
- Value
- aggregate gross proceeds of approximately $16.0 million
- Effective
- 2024-03-11
Exact text from the filing
On March 11, 2024, Aprea Therapeutics, Inc. (the "Company") entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain investors (the "Purchasers"), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 1,687,712 shares (the "Private Placement Shares") of the Company’s Common Stock, par value $0.001 per share ("Common Stock") at a purchase price of $7.29 per share, (ii) pre-funded Common Stock purchase warrants (the "Pre-Funded Warrants") to purchase an aggregate of up to 507,076 shares of Common Stock at an exercise price of $0.001 per share, (iii) Tranche A Common Stock purchase warrants to purchase up to 1,097,394 shares of Common Stock at an exercise price of $7.29 per share (the "Tranche A Warrants"), and (iv) Tranche B Common Stock purchase warrants to purchase up to 1,097,394 shares of Common Stock at an exercise price of $9.1125 per share (the "Tranche B Warrants"
View on SEC.gov